EXEMESTANE

Trials studying EXEMESTANE

• phase2A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatmentactive not recruitingn=333
• phase3A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapyrecruitingn=4,300
• phase3Phase IIIb Study of Ribociclib + ET in Early Breast Cancerrecruitingn=1,400
• phase3OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Canceractive not recruitingn=510
• phase3An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)active not recruitingn=5,511
• phase3Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)recruitingn=220
• phase3Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancerrecruitingn=788
• phase1A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumorsrecruitingn=260